Teachers Retirement System of The State of Kentucky lowered its stake in shares of The Medicines Company (NASDAQ:MDCO) by 71.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,090 shares of the company’s stock after selling 114,865 shares during the period. Teachers Retirement System of The State of Kentucky owned 0.06% of The Medicines worth $1,260,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of MDCO. Swiss National Bank increased its stake in shares of The Medicines by 1.6% during the 3rd quarter. Swiss National Bank now owns 120,650 shares of the company’s stock worth $4,469,000 after purchasing an additional 1,900 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of The Medicines by 41.1% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 24,060 shares of the company’s stock worth $891,000 after purchasing an additional 7,010 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of The Medicines during the 3rd quarter worth approximately $171,000. SG Americas Securities LLC purchased a new stake in shares of The Medicines during the 3rd quarter worth approximately $198,000. Finally, Macquarie Group Ltd. increased its stake in shares of The Medicines by 12.0% during the 3rd quarter. Macquarie Group Ltd. now owns 978,051 shares of the company’s stock worth $36,227,000 after purchasing an additional 104,869 shares during the last quarter.
Several equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Thursday, March 15th. Oppenheimer set a $50.00 price target on shares of The Medicines and gave the stock a “buy” rating in a research note on Monday, March 12th. ValuEngine upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Zacks Investment Research lowered shares of The Medicines from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Jefferies Group restated a “buy” rating and set a $47.00 price target on shares of The Medicines in a research note on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $50.00.
The Medicines (NASDAQ:MDCO) last released its quarterly earnings data on Wednesday, February 21st. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.71). The Medicines had a negative net margin of 1,035.27% and a negative return on equity of 316.40%. The business had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $20.71 million. During the same quarter in the prior year, the firm posted ($1.19) earnings per share. The firm’s quarterly revenue was down 50.6% on a year-over-year basis. research analysts forecast that The Medicines Company will post -2.71 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/03/21/the-medicines-company-mdco-shares-sold-by-teachers-retirement-system-of-the-state-of-kentucky.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.